Drug Trial Radar · NCT03934567
A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma
Last checked: Nov 19, 2026Latest source record: Apr 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
87
Actual
Start
Apr 22, 2020
Primary completion
Jan 29, 2025
Study completion Oct 30, 2025
Sponsor
- Lead sponsor
- Xynomic Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 2, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An open-label, single-arm, multi-center phase 2 study to evaluate the efficacy and safety of oral histone deacetylase (HDAC)-inhibitor abexinostat, as monotherapy in patients with relapsed or refractory follicular lymphoma (FL)
Conditions
- Lymphoma, Follicular
Interventions
AbexinostatDrug
Abexinostat tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical effect of abexinostat on objective response rate as assessed by an independent central imaging reviewTime frame: up to 56 days
Locations
26 sites in 1 country. Site status is shown where the registry gives one.
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, China
China-Japan Friendship Hospital
Beijing, China
Peking University Third Hospital
Beijing, China
Jilin Cancer Hospital
Changchun, China
West China Hospital, Sichuan University
Chengdu, China
The First Affiliated Hospital of Dalian Medical University
Dalian, China
Fujian Medical University Union Hospital
Fuzhou, China
Cancer Center of Guangzhou Medical University
Guangzhou, China
Sun Yai-Sen Memorial Hospital, Sun Yai-Sen University
Guangzhou, China
Nanfang Hospital
Guangzhou, China
Hainan General Hospital
Hainan, China
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, China
Sir Run Run Shaw Hospital, Zhejiang University School of Medical
Hangzhou, China
Zhejiang Cancer Hospital
Hangzhou, China
The Affiliated Tumor Hospital of Harbin Medical University
Harbin, China
The First Hospital of Lanzhou University
Lanzhou, China
Linyi Cancer Hospital
Linyi, China
Nantong Tumor Hospital
Nantong, China
Shanghai Sixth people's hospital
Shanghai, China
Fudan University Shanghai Cancer Center
Shanghai, China
The Forth Hospital of Hebei Medical University
Shijiazhuang, China
Tianjin People's Hospital
Tianjin, China
Tianjin Medical University General Hospital
Tianjin, China
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, China
Henan Cancer Hospital
Zhengzhou, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.